TW457247B - Novel antigen - Google Patents

Novel antigen Download PDF

Info

Publication number: TW457247B
Authority: TW; Taiwan
Prior art keywords: protein; omp26; page; amino acid; ministry
Prior art date: 1995-06-27

Application number

TW085111139A

Other languages

English (en)

Chinese (zh)

Inventor

Jennelle Kyd

Allan Cripps

Christopher John Smith

Original Assignee

Cortecs Internat Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-27

Filing date

1996-09-12

Publication date

2001-10-01

1996-09-12 Application filed by Cortecs Internat Ltd filed Critical Cortecs Internat Ltd

2001-10-01 Application granted granted Critical

2001-10-01 Publication of TW457247B publication Critical patent/TW457247B/zh

Links

239000000427 antigen Substances 0.000 title description 12
102000036639 antigens Human genes 0.000 title description 12
108091007433 antigens Proteins 0.000 title description 12
108090000623 proteins and genes Proteins 0.000 claims abstract description 66
102000004169 proteins and genes Human genes 0.000 claims abstract description 65
241000606768 Haemophilus influenzae Species 0.000 claims abstract description 27
229960005486 vaccine Drugs 0.000 claims abstract description 13
230000000890 antigenic effect Effects 0.000 claims abstract description 6
229940047650 haemophilus influenzae Drugs 0.000 claims description 16
150000001413 amino acids Chemical class 0.000 claims description 14
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 9
108090000765 processed proteins & peptides Proteins 0.000 claims description 8
101710116435 Outer membrane protein Proteins 0.000 claims description 7
230000002079 cooperative effect Effects 0.000 claims description 6
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 5
239000002671 adjuvant Substances 0.000 claims description 4
239000000969 carrier Substances 0.000 claims description 3
125000003275 alpha amino acid group Chemical group 0.000 claims 2
108020001507 fusion proteins Proteins 0.000 claims 1
102000037865 fusion proteins Human genes 0.000 claims 1
230000003053 immunization Effects 0.000 abstract description 12
238000000034 method Methods 0.000 abstract description 12
108091028043 Nucleic acid sequence Proteins 0.000 abstract description 7
208000015181 infectious disease Diseases 0.000 abstract description 6
238000001514 detection method Methods 0.000 abstract description 5
239000012528 membrane Substances 0.000 abstract description 5
206010057190 Respiratory tract infections Diseases 0.000 abstract description 3
206010033078 Otitis media Diseases 0.000 abstract description 2
238000011321 prophylaxis Methods 0.000 abstract 1
208000020029 respiratory tract infectious disease Diseases 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1
101100406392 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) omp26 gene Proteins 0.000 description 71
235000018102 proteins Nutrition 0.000 description 52
241000894006 Bacteria Species 0.000 description 33
241000700159 Rattus Species 0.000 description 30
210000004072 lung Anatomy 0.000 description 18
241001465754 Metazoa Species 0.000 description 17
210000004369 blood Anatomy 0.000 description 15
239000008280 blood Substances 0.000 description 15
238000002649 immunization Methods 0.000 description 11
238000012360 testing method Methods 0.000 description 11
238000004458 analytical method Methods 0.000 description 10
239000000499 gel Substances 0.000 description 10
210000004027 cell Anatomy 0.000 description 9
241000382353 Pupa Species 0.000 description 8
108020004414 DNA Proteins 0.000 description 7
235000001014 amino acid Nutrition 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
230000035755 proliferation Effects 0.000 description 6
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
230000008030 elimination Effects 0.000 description 5
238000003379 elimination reaction Methods 0.000 description 5
239000012530 fluid Substances 0.000 description 5
238000011081 inoculation Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
235000019333 sodium laurylsulphate Nutrition 0.000 description 5
239000000284 extract Substances 0.000 description 4
230000028993 immune response Effects 0.000 description 4
230000036039 immunity Effects 0.000 description 4
NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 4
210000001165 lymph node Anatomy 0.000 description 4
210000001539 phagocyte Anatomy 0.000 description 4
239000000243 solution Substances 0.000 description 4
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
208000002109 Argyria Diseases 0.000 description 3
102000004533 Endonucleases Human genes 0.000 description 3
108010042407 Endonucleases Proteins 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
241000607477 Yersinia pseudotuberculosis Species 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
210000002706 plastid Anatomy 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
238000011160 research Methods 0.000 description 3
235000020183 skimmed milk Nutrition 0.000 description 3
239000002689 soil Substances 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 2
241000283707 Capra Species 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
239000002033 PVDF binder Substances 0.000 description 2
241000606856 Pasteurella multocida Species 0.000 description 2
239000006180 TBST buffer Substances 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
238000003277 amino acid sequence analysis Methods 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
-1 leucine Amino acids Chemical class 0.000 description 2
239000000463 material Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
150000007523 nucleic acids Chemical group 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
JSFWKIGZJUSYJD-UHFFFAOYSA-N 2-(9h-fluoren-1-yl)ethanol Chemical compound C1C2=CC=CC=C2C2=C1C(CCO)=CC=C2 JSFWKIGZJUSYJD-UHFFFAOYSA-N 0.000 description 1
ZZICNFCOOZFLMP-UHFFFAOYSA-N 2-bromo-2-chloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Br.FC(F)(F)C(Cl)Br ZZICNFCOOZFLMP-UHFFFAOYSA-N 0.000 description 1
RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
241000269333 Caudata Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
235000001543 Corylus americana Nutrition 0.000 description 1
240000007582 Corylus avellana Species 0.000 description 1
235000007466 Corylus avellana Nutrition 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
101001113903 Grapevine leafroll-associated virus 3 (isolate United States/NY1) Protein P4 Proteins 0.000 description 1
206010061190 Haemophilus infection Diseases 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
241000239218 Limulus Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
101710167675 Outer membrane protein P5 Proteins 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
102100035181 Plastin-1 Human genes 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
BHATUINFZWUDIX-UHFFFAOYSA-N Zwittergent 3-14 Chemical compound CCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O BHATUINFZWUDIX-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
210000003111 iliac vein Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000007689 inspection Methods 0.000 description 1
235000014705 isoleucine Nutrition 0.000 description 1
125000000741 isoleucyl group Chemical class [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
239000006166 lysate Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229960000907 methylthioninium chloride Drugs 0.000 description 1
ACXCKRZOISAYHH-UHFFFAOYSA-N molecular chlorine hydrate Chemical compound O.ClCl ACXCKRZOISAYHH-UHFFFAOYSA-N 0.000 description 1
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
229940051027 pasteurella multocida Drugs 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
108010049148 plastin Proteins 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
239000012898 sample dilution Substances 0.000 description 1
238000007790 scraping Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000011870 unpaired t-test Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
239000004474 valine Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Biophysics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Hematology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Plant Pathology (AREA)
Virology (AREA)
Food Science & Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)

TW085111139A 1995-06-27 1996-09-12 Novel antigen TW457247B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9513074.6A GB9513074D0 (en)	1995-06-27	1995-06-27	Novel anigen

Publications (1)

Publication Number	Publication Date
TW457247B true TW457247B (en)	2001-10-01

Family

ID=10776746

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW085111139A TW457247B (en)	1995-06-27	1996-09-12	Novel antigen

Country Status (18)

Country	Link
US (4)	US6245338B1 (2)
EP (1)	EP0835313B1 (2)
JP (2)	JPH11510373A (2)
KR (1)	KR19990028423A (2)
CN (1)	CN1144875C (2)
AT (1)	ATE317013T1 (2)
AU (1)	AU708061B2 (2)
CA (1)	CA2225405A1 (2)
DE (1)	DE69635783T2 (2)
ES (1)	ES2259443T3 (2)
GB (1)	GB9513074D0 (2)
MX (1)	MX9710412A (2)
NO (1)	NO976119L (2)
NZ (1)	NZ311120A (2)
RU (1)	RU2221045C2 (2)
TW (1)	TW457247B (2)
WO (1)	WO1997001638A1 (2)
ZA (1)	ZA965482B (2)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6468765B1 (en)	1995-04-21	2002-10-22	Human Genome Sciences, Inc.	Selected Haemophilus influenzae Rd polynucleotides and polypeptides
US6355450B1 (en)	1995-04-21	2002-03-12	Human Genome Sciences, Inc.	Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
GB9904183D0 (en) *	1999-02-24	1999-04-14	Smithkline Beecham Biolog	Novel compounds
ES2275499T3 (es)	1999-03-19	2007-06-16	Glaxosmithkline Biologicals S.A.	Vacuna contra streptococcus pneumoniae.
GB0022742D0 (en)	2000-09-15	2000-11-01	Smithkline Beecham Biolog	Vaccine
EP2088197B8 (en) *	2000-10-02	2016-07-20	ID Biomedical Corporation of Quebec	Haemophilus influenzae antigens and corresponding DNA fragments
RU2185191C1 (ru) *	2001-02-01	2002-07-20	Ростовский научно-исследовательский институт микробиологии и паразитологии	Способ получения антигенного препарата haemophilus influenzae типа b (hib)
GB0103171D0 (en)	2001-02-08	2001-03-28	Smithkline Beecham Biolog	Vaccine composition
EP1524991A1 (en)	2002-08-02	2005-04-27	GlaxoSmithKline Biologicals S.A.	Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
CN101687025A (zh) *	2005-03-30	2010-03-31	诺华疫苗和诊断公司	B型流感嗜血杆菌
CN100357318C (zh) *	2005-10-11	2007-12-26	中山大学	美人鱼发光杆菌外膜蛋白w和编码序列及其制备方法和应用
KR100743604B1 (ko) *	2005-12-05	2007-07-27	볼보 컨스트럭션 이키프먼트 홀딩 스웨덴 에이비	차량용 머플러 구조
TWI457133B (zh)	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
PL1973564T3 (pl)	2005-12-22	2017-04-28	Glaxosmithkline Biologicals S.A.	Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
AU2007206114B2 (en)	2006-01-17	2013-01-24	Arne Forsgren	A novel surface exposed Haemophilus influenzae protein (protein E; pE)
SI2167121T1 (sl)	2007-06-26	2015-12-31	Glaxosmithkline Biologicals S.A.	Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
GB201003922D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Conjugation process
GB201003924D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Immunogenic composition
EP2544714A1 (en)	2010-03-10	2013-01-16	GlaxoSmithKline Biologicals S.A.	Vaccine composition
GB201103836D0 (en)	2011-03-07	2011-04-20	Glaxosmithkline Biolog Sa	Conjugation process
US20130156803A1 (en)	2011-06-04	2013-06-20	Rochester General Hospital Research Institute	Compositions and methods related to p6
CN104321078A (zh) *	2012-04-26	2015-01-28	诺华股份有限公司	抗原和抗原组合
CN104370997B (zh) *	2014-09-24	2018-07-31	陈辉	去除生物制品中细菌内毒素的试剂盒、方法及其生物制品的制备方法
GB201518684D0 (en)	2015-10-21	2015-12-02	Glaxosmithkline Biolog Sa	Vaccine
GB201621686D0 (en)	2016-12-20	2017-02-01	Glaxosmithkline Biologicals Sa	Novel methods for inducing an immune response
CA3063954A1 (en)	2017-05-30	2018-12-06	Glaxosmithline Biologicals S.A.	Methods for manufacturing an adjuvant
BR112020010790A2 (pt)	2017-12-01	2020-11-10	Glaxosmithkline Biologicals S.A.	purificação da saponina
US20210283238A1 (en)	2018-08-07	2021-09-16	Glaxosmithkline Biologicals Sa	Novel processes and vaccines
WO2020109365A1 (en)	2018-11-29	2020-06-04	Glaxosmithkline Biologicals Sa	Methods for manufacturing an adjuvant
JP7640473B2 (ja)	2019-06-05	2025-03-05	グラクソスミスクラインバイオロジカルズソシエテアノニム	サポニン精製
US10973908B1 (en)	2020-05-14	2021-04-13	David Gordon Bermudes	Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en)	2020-07-22	2026-01-27	David Gordon Bermudes	Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
GB202205833D0 (en)	2022-04-21	2022-06-08	Glaxosmithkline Biologicals Sa	Bacteriophage
WO2024017827A1 (en)	2022-07-19	2024-01-25	Glaxosmithkline Biologicals Sa	Continuous process for vaccine production

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69033600T2 (de) *	1989-03-09	2001-04-05	American Cyanamid Co., Madison	Verfahren zur Isolierung von Haemopnilus influenzae Protein-E
GB8924473D0 (en) *	1989-10-31	1989-12-20	Connaught Lab	Outer membrane protein p1 and peptides of haemophilus influenzae b
GB9224584D0 (en) *	1992-11-23	1993-01-13	Connaught Lab	Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases

1995
- 1995-06-27 GB GBGB9513074.6A patent/GB9513074D0/en active Pending
1996
- 1996-06-27 ZA ZA9605482A patent/ZA965482B/xx unknown
- 1996-06-27 AT AT96920996T patent/ATE317013T1/de not_active IP Right Cessation
- 1996-06-27 ES ES96920996T patent/ES2259443T3/es not_active Expired - Lifetime
- 1996-06-27 JP JP9504247A patent/JPH11510373A/ja active Pending
- 1996-06-27 WO PCT/GB1996/001549 patent/WO1997001638A1/en not_active Ceased
- 1996-06-27 DE DE69635783T patent/DE69635783T2/de not_active Expired - Lifetime
- 1996-06-27 AU AU62363/96A patent/AU708061B2/en not_active Ceased
- 1996-06-27 NZ NZ311120A patent/NZ311120A/en not_active IP Right Cessation
- 1996-06-27 CN CNB961951389A patent/CN1144875C/zh not_active Expired - Fee Related
- 1996-06-27 RU RU98101249/13A patent/RU2221045C2/ru not_active IP Right Cessation
- 1996-06-27 CA CA002225405A patent/CA2225405A1/en not_active Abandoned
- 1996-06-27 EP EP96920996A patent/EP0835313B1/en not_active Expired - Lifetime
- 1996-06-27 KR KR1019970709739A patent/KR19990028423A/ko not_active Ceased
- 1996-09-12 TW TW085111139A patent/TW457247B/zh not_active IP Right Cessation
1997
- 1997-12-18 MX MX9710412A patent/MX9710412A/es not_active IP Right Cessation
- 1997-12-22 US US08/996,408 patent/US6245338B1/en not_active Expired - Fee Related
- 1997-12-29 NO NO976119A patent/NO976119L/no not_active Application Discontinuation
1999
- 1999-05-13 US US09/310,847 patent/US6254875B1/en not_active Expired - Fee Related
- 1999-05-13 US US09/310,845 patent/US6284477B1/en not_active Expired - Fee Related
2000
- 2000-04-12 US US09/548,023 patent/US6313281B1/en not_active Expired - Fee Related
2008
- 2008-09-03 JP JP2008226372A patent/JP2009034107A/ja active Pending

Also Published As

Publication number	Publication date
AU6236396A (en)	1997-01-30
RU2221045C2 (ru)	2004-01-10
DE69635783T2 (de)	2006-11-02
WO1997001638A1 (en)	1997-01-16
JPH11510373A (ja)	1999-09-14
KR19990028423A (ko)	1999-04-15
US6284477B1 (en)	2001-09-04
AU708061B2 (en)	1999-07-29
CN1144875C (zh)	2004-04-07
JP2009034107A (ja)	2009-02-19
NO976119D0 (no)	1997-12-29
EP0835313A1 (en)	1998-04-15
US6313281B1 (en)	2001-11-06
US6254875B1 (en)	2001-07-03
EP0835313B1 (en)	2006-02-01
ES2259443T3 (es)	2006-10-01
DE69635783D1 (de)	2006-04-13
CN1189186A (zh)	1998-07-29
MX9710412A (es)	1998-07-31
GB9513074D0 (en)	1995-08-30
NO976119L (no)	1998-02-26
NZ311120A (en)	1999-10-28
ATE317013T1 (de)	2006-02-15
CA2225405A1 (en)	1997-01-16
US6245338B1 (en)	2001-06-12
ZA965482B (en)	1997-12-29

Legal Events

Date	Code	Title	Description
2002-03-04	GD4A	Issue of patent certificate for granted invention patent
2012-07-01	MM4A	Annulment or lapse of patent due to non-payment of fees

Publication	Publication Date	Title
TW457247B (en)	2001-10-01	Novel antigen
Ruffolo et al.	1996	Cloning, sequencing, expression, and protective capacity of the oma87 gene encoding the Pasteurella multocida 87-kilodalton outer membrane antigen
CN103893747B (zh)	2016-01-06	增强针对艾美球虫属的免疫反应的组合物和方法
Kyd et al.	1995	Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model
JP4583607B2 (ja)	2010-11-17	感染症の治療のための弱毒化微生物
Angerman et al.	1978	Comparative efficacy and toxicity of a ribosomal vaccine, acetone-killed cells, lipopolysaccharide, and a live cell vaccine prepared from Salmonella typhhimurium
CN102971008B (zh)	2015-11-25	降低弯曲菌属感染的疫苗和方法
US20080069844A1 (en)	2008-03-20	Mucosal Vaccine Adjuvants Containing Bacterial Flagellins as an Active Component
US20200246443A1 (en)	2020-08-06	Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase)
JP4982009B2 (ja)	2012-07-25	ナイセリアワクチン組成物および方法
CN114099659A (zh)	2022-03-01	结核分枝杆菌Rv0934抗原蛋白、其抗原表位肽及其应用
Roberts et al.	1993	Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P. 69 and FHA
EP0359919A2 (en)	1990-03-28	Recombinant mycoplasma hyopneumoniae antigen and uses therefor
US6660261B1 (en)	2003-12-09	Bordetella strain expressing the FHA hybrid, liposomes and vaccines
US7081244B2 (en)	2006-07-25	Neisserial vaccine compositions and methods
KR101991577B1 (ko)	2019-06-20	다수의 에피토프로 구성된 재조합 항원 단백질 및 이의 제조방법
JP2009029825A (ja)	2009-02-12	抗原
EP0358692B1 (en)	1998-06-03	Cholera vaccines
CN111150839A (zh)	2020-05-15	一种用于免疫接种的组合物及其制备方法
CN118930658A (zh)	2024-11-12	一种基于细菌样颗粒的炭疽芽胞杆菌疫苗
Moore	1991	crja4/^ Yf _
WO2005096823A1 (en)	2005-10-20	Vaccine for nontypeable haemophilus influenzae infection